Drug intelligence / Profile preview

NGF4-B

Development stage: Preclinical
Lead developer: Alcon
Modality: Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Ophthalmic

Overview

NGF4-B is a test formulation developed by Alcon Research for an artificial tear product. It is being evaluated for its safety and tolerability profile as an ocular lubricant, with administration via eye drops. Artificial tears are commonly used to provide temporary relief from burning and irritation due to dryness of the eye by supplementing the natural tear film and enhancing lubrication.

Beyond the preview

Go deeper on NGF4-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NGF4-B.

Explore the full profile